Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 in India in May from April in its second full ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...